ELISA
LUÑO FERNANDEZ
Investigador/a
Hospital Universitario La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (41)
2019
-
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155
2018
-
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
British Journal of Haematology, Vol. 181, Núm. 3, pp. 350-359
-
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance
Genes Chromosomes and Cancer, Vol. 57, Núm. 11, pp. 547-556
-
Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes
Blood Advances, Vol. 2, Núm. 16, pp. 2079-2089
-
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: A European LeukemiaNet study
Leukemia, Vol. 32, Núm. 6, pp. 1380-1392
-
Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS
Leukemia Research, Vol. 67, pp. 21-26
2017
-
Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
Leukemia Research, Vol. 63, pp. 85-89
-
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
American Journal of Hematology, Vol. 92, Núm. 7, pp. 614-621
-
Excess mortality in the myelodysplastic syndromes
American Journal of Hematology, Vol. 92, Núm. 2, pp. 149-154
-
Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group
American Journal of Hematology, Vol. 92, Núm. 9, pp. E534-E541
2016
-
Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes
Journal of Clinical Oncology, Vol. 34, Núm. 27, pp. 3284-3292
-
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: A rationale for its inclusion into future classifications of myelodysplastic syndromes
Modern Pathology, Vol. 29, Núm. 12, pp. 1541-1551
-
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924
-
Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
Genes Chromosomes and Cancer, Vol. 55, Núm. 4, pp. 322-327
2015
-
Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations
British Journal of Haematology
-
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry
Leukemia, Vol. 29, Núm. 9, pp. 1875-1881
-
Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes
Leukemia and Lymphoma, Vol. 56, Núm. 11, pp. 3183-3188
-
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study
The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266
-
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry
British Journal of Haematology, Vol. 170, Núm. 3, pp. 372-383
2014
-
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201